ProfileGDS5678 / 1435387_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 43% 42% 40% 41% 40% 40% 41% 41% 44% 49% 45% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0261543
GSM967853U87-EV human glioblastoma xenograft - Control 22.9876543
GSM967854U87-EV human glioblastoma xenograft - Control 32.9637642
GSM967855U87-EV human glioblastoma xenograft - Control 42.8763140
GSM967856U87-EV human glioblastoma xenograft - Control 52.9059541
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0146540
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9745240
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9435941
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9285741
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.004744
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1569849
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0217945
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9541341
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9516341